… by The National Cancer Institute Common Toxicity Criteria version 3.0 (Table 7). Prospective
trials are needed to further investigate the correlation between anti-EGFR therapy and rash …

… cancer cells, genetic modifications could enable them to acquire a resistant phenotype to
anti-EGFR therapies… the molecular mechanisms affecting cancer cell sensitivity or resistance to …

… for anti-EGFR therapy include early and advanced stage, and metastatic breast cancer as well
as an array of other solid tumors … studies suggest that various anti-EGFR/TKI combinations …

… anti-EGFR therapy and present and overview of the possible mechanisms that may contribute
to the development of primary and secondary resistance to anti-EGFR therapy in mCRC. …

… antibodies in preclinical models was confirmed in clinical samples from patients with colorectal
cancer at relapse after anti-EGFR treatment. Bettegowda and colleagues (77) analyzed …

… with patients with RAS WT tumors. A recent large … for anti-EGFR therapy by lowering the
threshold in tissue samples from 5% to 1% MAF. As expected, in this study anti-EGFR treatment …

… studies of EGFR therapies and potential resistant mechanisms against anti-EGFR therapies
in various cancer types and discuss the perspective on anti-EGFR therapies in TNBC. …

… and the role of EGFR signaling in cancer progression. Furthermore, current developments
… for the treatment of epithelial cancers and a summary of the various anti-EGFR therapeutic …

… CRC becomes resistant to anti-EGFR therapy, we believe that additional research should
be directed toward understanding and controlling the evolutionary process in tumors, paying …

… signaling pathways for cancer therapy. Below we discuss various aspects of EGFR-targeted
therapies mainly in hematologic malignancies, lung cancer and breast cancer. Beside novel …